Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ward Knutson who wrote (7214)	11/21/1999 10:41:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9719

Ward: I still hold some MOGN. I've been correct about the stock to date, and I was correct early......... techstocks.com >> 47% is NOT the final number << Red flags should come up when a company brags about an observation that is formally a nonresponse. I spell it "T-A-C-K-Y". FDA may spell it "I-N-F-U-R-I-A-T-I-N-G". You're angry and citing results with three patients. >> "Blitzer is a fool for not licensing the drug out long ago to protect Salagen profits" << Please don't use quotes when you're paraphrasing in anger, particularly when you took the initial comments and put your own spin on them. I believe that it would have been wise to license 114 and move on to develop the niche product business. At that time, Blitzer himself was indicating that it was his first priority to license 114 in Europe, and he was also still describing the business as addressing niche pharmaceuticals. I don't give a rat's butt about Salagen..... I had hoped that the company could take those Salagen profits and build on the portfolio of niche products and use 114 funding as leverage. I would have been happy with a slow ten bagger. >> Richard it strikes me that your distaste for Blitzer's style is clouding your view of what a tremendous impact 114 is likely to have both in the world of oncology and MGI Pharma's potential for explosive growth. << Be sure to come back and tell me again, when the data rather than your gut tells those stories. With respect to my distaste for Blitzer..... those who came before him are responsible for the success to date. He has added this game -- this gamble -- of leveraged risk. I hope it works. I do think it's foolish to take a secure growth story and turn it into a situation which risks both jobs and investor's $$$. >> BTW, your free cash-flow calculations are inaccurate. << I was just simply using wording that is common among investors. $950K from last quarter, annualized going forward, is 4M.